China on the Move: Lesson from China's National Negotiation of Drug Prices in 2021 | Insights
In December 2021, China’s National Healthcare Security Administration (NHSA) published the 2021 National Reimbursement Drug List (2021 NRDL), implementing greater pricing discounts than those seen in 2020.
Hunan Province United States Junshi Toripalimab Adcs Trastuzumab Emtansine Novartis Zolgensma Beigene Tislelizumab
Source: gtlaw.com